Genocea Biosciences Inc (NASDAQ:GNCA)’s share price rose 9.5% during mid-day trading on Thursday . The stock traded as high as $1.19 and last traded at $1.15. Approximately 967,999 shares were traded during trading, an increase of 60% from the average daily volume of 606,500 shares. The stock had previously closed at $1.05.

GNCA has been the topic of several research analyst reports. Zacks Investment Research upgraded Genocea Biosciences from a “hold” rating to a “buy” rating and set a $1.75 price target on the stock in a research report on Monday, October 16th. Cowen restated a “buy” rating and issued a $10.00 target price on shares of Genocea Biosciences in a report on Tuesday, September 26th. Stifel Nicolaus cut Genocea Biosciences from a “buy” rating to a “hold” rating and decreased their target price for the stock from $15.00 to $2.50 in a report on Monday, September 25th. Needham & Company LLC cut Genocea Biosciences from a “buy” rating to a “hold” rating in a report on Tuesday, September 26th. Finally, Piper Jaffray Companies restated an “overweight” rating and issued a $5.00 target price on shares of Genocea Biosciences in a report on Thursday, November 2nd. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and three have given a buy rating to the stock. Genocea Biosciences presently has an average rating of “Hold” and a consensus price target of $6.25.

The company has a market cap of $33.01, a PE ratio of -0.53 and a beta of 1.94. The company has a quick ratio of 1.55, a current ratio of 1.55 and a debt-to-equity ratio of 2.51.

Genocea Biosciences (NASDAQ:GNCA) last issued its earnings results on Thursday, November 2nd. The biotechnology company reported ($0.59) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.51) by ($0.08). During the same period last year, the business earned ($0.45) earnings per share. sell-side analysts predict that Genocea Biosciences Inc will post -1.91 EPS for the current year.

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Vanguard Group Inc. lifted its position in shares of Genocea Biosciences by 13.9% in the second quarter. Vanguard Group Inc. now owns 856,762 shares of the biotechnology company’s stock worth $4,472,000 after buying an additional 104,790 shares during the last quarter. Northern Trust Corp increased its stake in Genocea Biosciences by 642.9% during the second quarter. Northern Trust Corp now owns 306,597 shares of the biotechnology company’s stock valued at $1,601,000 after acquiring an additional 265,328 shares during the period. OxFORD Asset Management LLP bought a new position in Genocea Biosciences during the second quarter valued at about $204,000. GSA Capital Partners LLP bought a new stake in shares of Genocea Biosciences in the 2nd quarter valued at approximately $100,000. Finally, State of Wisconsin Investment Board bought a new stake in shares of Genocea Biosciences in the 2nd quarter valued at approximately $125,000. 34.69% of the stock is owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION NOTICE: “Genocea Biosciences (GNCA) Stock Price Up 9.5%” was originally reported by Watch List News and is owned by of Watch List News. If you are accessing this article on another publication, it was illegally copied and reposted in violation of U.S. and international trademark & copyright laws. The legal version of this article can be accessed at https://www.watchlistnews.com/genocea-biosciences-gnca-stock-price-up-9-5/1803712.html.

About Genocea Biosciences

Genocea Biosciences, Inc, is harnessing the power of T cell immunity to develop vaccines and immunotherapies company. The Company uses its discovery platform, AnTigen Lead Acquisition System (ATLAS), to design vaccines and immunotherapies that act, in part, through T cell (or cellular) immune responses.

Receive News & Ratings for Genocea Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.